Page 1 | Search Results | Blood | American Society of Hematology

1-7 of 7

Sort by

Sort Order Select

Journal Articles

MYC Translocations Identified By Sequencing Panel in Smoldering Multiple Myeloma Strongly Predict for Rapid Progression to Multiple Myeloma

Niamh Keane, MB, MRCP, Caleb K Stein, MS, Daniel Angelov, MSc,MB, Shulan Tian, David Viswanatha, MD, Shaji K Kumar, MD, Angela Dispenzieri, MD, Veronica Gonzalez De La Calle, MD, Kristine Misund, PhD, Robert A Kyle, MD, Michael E O'Dwyer, MD, Rafael Fonseca, MD, A. Keith Stewart, MBChB, MBA, Esteban Braggio, PhD, Yan Asmann, PhD, S. Vincent Rajkumar, MD, P. Leif Bergsagel, MD

Blood (2017) 130 (Supplement 1): 393.

https://doi.org/10.1182/blood.V130.Suppl_1.393.393

Published: 2017

Journal Articles

Complementary Activation of Ccnd, MYC, RAS and NFkB By Mutations in Multiple Myeloma

Kristine Misund, PhD, Niamh Keane, MD, Yan W Asmann, PhD, Scott Van Wier, Daniel Riggs, PhD, Gregory Ahmann, Marta Chesi, PhD, K. Martin Körtum, MD, Rafael Fonseca, MD, A. Keith Stewart, MD, Esteban Braggio, PhD, P. Leif Bergsagel, MD

Blood (2016) 128 (22): 355.

https://doi.org/10.1182/blood.V128.22.355.355

Published: 2016

Journal Articles

Concurrent Inhibition of Pim and Akt Pathways with Pim447 and Afuresertib Activates FOXO3a and Depletes c-Myc to Induce Synergistic Cell Death in Multiple Myeloma

Niamh Keane, MB BCh MRCPI, Mairead Reidy, PhD, Alessandro Natoni, PhD, Michael O'Dwyer, MD FRCPI, FRCPath

Blood (2015) 126 (23): 3007.

https://doi.org/10.1182/blood.V126.23.3007.3007

Published: 2015

Journal Articles

E-Selectin Ligand Expression Increases with Progression of Myeloma and Induces Drug Resistance in a Murine Transplant Model, Which Is Overcome By the Glycomimetic E-Selectin Antagonist, GMI-1271

Alessandro Natoni, PhD, Theodore A.G. Smith, PhD, Niamh Keane, MB, MRCP, Silvia C. Locatelli-Hoops, PhD, Isabela Oliva, William E. Fogler, PhD, John L. Magnani, PhD, Michael O'Dwyer, MD

Blood (2015) 126 (23): 1805.

https://doi.org/10.1182/blood.V126.23.1805.1805

Published: 2015

Journal Articles

Initial Evaluation of Novel Dual PIM/PI3K and Triple PIM/PI3K/mTOR Inhibitors in Multiple Myeloma

Mairead Reidy, PhD, Marianne vanDijk, PhD, Niamh Keane, MB BCh BAO, Michael O'Neill, PhD, Michael E O'Dwyer, MD FRCPI, FRCPath

Blood (2014) 124 (21): 5713.

https://doi.org/10.1182/blood.V124.21.5713.5713

Published: 2014

Journal Articles

Cytogenetic Abnormalities Predict Clinical Outcome In Patients Diagnosed With Relapsed Acute Myeloid Leukemia (rAML): Single Center Experience

Hassan Alkhateeb, MD, Rhett P Ketterling, Niamh Keane, Mrinal M Patnaik, MBBS, Animesh Pardanani, MBBS, PhD, Michelle Elliott, MD, William J Hogan, MD, Mark R. Litzow, MD, Aref Al-Kali, MD

Blood (2013) 122 (21): 4955.

https://doi.org/10.1182/blood.V122.21.4955.4955

Published: 2013

Journal Articles

FLT3 Mutation Predicts Worse Clinical Outcome of Relapsed Acute Myeloid Leukemia (rAML) Patients (Pts): Mayo Clinic Experience.

Ahmed Elkhanany, Niamh Keane, Alexandra Wolanskyj, William Hogan, Michelle Elliott, Mark Litzow, MD, Aref Al-Kali, MD

Blood (2012) 120 (21): 2525.

https://doi.org/10.1182/blood.V120.21.2525.2525

Published: 2012

NARROW

MYC Translocations Identified By Sequencing Panel in Smoldering Multiple Myeloma Strongly Predict for Rapid Progression to Multiple Myeloma

Complementary Activation of Ccnd, MYC, RAS and NFkB By Mutations in Multiple Myeloma

Concurrent Inhibition of Pim and Akt Pathways with Pim447 and Afuresertib Activates FOXO3a and Depletes c-Myc to Induce Synergistic Cell Death in Multiple Myeloma

E-Selectin Ligand Expression Increases with Progression of Myeloma and Induces Drug Resistance in a Murine Transplant Model, Which Is Overcome By the Glycomimetic E-Selectin Antagonist, GMI-1271

Initial Evaluation of Novel Dual PIM/PI3K and Triple PIM/PI3K/mTOR Inhibitors in Multiple Myeloma

Cytogenetic Abnormalities Predict Clinical Outcome In Patients Diagnosed With Relapsed Acute Myeloid Leukemia (rAML): Single Center Experience

FLT3 Mutation Predicts Worse Clinical Outcome of Relapsed Acute Myeloid Leukemia (rAML) Patients (Pts): Mayo Clinic Experience.

Email alerts

ASH Publications

American Society of Hematology

MYC Translocations Identified By Sequencing Panel in Smoldering Multiple Myeloma Strongly Predict for Rapid Progression to Multiple Myeloma

Complementary Activation of Ccnd, MYC, RAS and NFkB By Mutations in Multiple Myeloma

Concurrent Inhibition of Pim and Akt Pathways with Pim447 and Afuresertib Activates FOXO3a and Depletes c-Myc to Induce Synergistic Cell Death in Multiple Myeloma

E-Selectin Ligand Expression Increases with Progression of Myeloma and Induces Drug Resistance in a Murine Transplant Model, Which Is Overcome By the Glycomimetic E-Selectin Antagonist, GMI-1271

Initial Evaluation of Novel Dual PIM/PI3K and Triple PIM/PI3K/mTOR Inhibitors in Multiple Myeloma

Cytogenetic Abnormalities Predict Clinical Outcome In Patients Diagnosed With Relapsed Acute Myeloid Leukemia (rAML): Single Center Experience

FLT3 Mutation Predicts Worse Clinical Outcome of Relapsed Acute Myeloid Leukemia (rAML) Patients (Pts): Mayo Clinic Experience.

Email alerts

ASH Publications

American Society of Hematology

This Feature Is Available To Subscribers Only